Global Blood Therapeutics Inc (GBT) Stock
GBT is no longer traded. Global Blood Therapeutics was acquired by Pfizer (PFE) on October 5, 2022.
Each GBT share was exchanged for $68.50 in cash. Prices on this page are historical; the last trade was October 4, 2022 at $68.49.
See Pfizer (PFE) stock →Global Blood Therapeutics stock price history
GBT final trading statistics
- Final close
- $68.49
- Final trading day
- Oct 4, 2022
- Market cap at delisting
- $4.62B
- Shares outstanding
- 67.48M
- Final 52-week range
- $21.65 – $73.02
- Avg. volume (final 3 mo.)
- 3,727,216
- All-time high (split-adj.)
- $87.20 · Jan 2020
- All-time low (split-adj.)
- $3.30 · Nov 2007
- Return since IPO
- +778.1%
- Beta
- 0.46
- Book value / share
- $1.76
- Price / book
- 38.94
Global Blood Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $194.75M | -$303.1M | -$4.82 |
| FY2020 | $123.80M | -$247.6M | -$4.03 |
| FY2019 | $2.11M | -$266.8M | -$4.54 |
| FY2018 | $0.00 | -$174.2M | -$3.41 |
| FY2017 | $0.00 | -$117.0M | -$2.75 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Global Blood Therapeutics Inc
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Global Blood Therapeutics stock FAQ
What happened to Global Blood Therapeutics stock?
Global Blood Therapeutics was acquired by Pfizer (PFE) on October 5, 2022. Shareholders received $68.50 in cash for each share. GBT stock stopped trading on the Nasdaq, with a final close of $68.49 on October 4, 2022.
What did Global Blood Therapeutics shareholders receive?
Each GBT share was converted into $68.50 in cash. The deal was valued at about $5.4 billion.
Is GBT stock still trading?
No. GBT was delisted from the Nasdaq on October 5, 2022 and no longer trades on a U.S. exchange.
What was the last price of GBT stock?
GBT closed at $68.49 on its final trading day, October 4, 2022, for a market value of about $4.62B.
What were Global Blood Therapeutics's revenue and earnings in its last full fiscal year?
Global Blood Therapeutics reported revenue of $194.75M and net income of -$303.1M in fiscal 2021, its last full year as a public company.
When did Global Blood Therapeutics go public?
Global Blood Therapeutics Inc stock began trading on August 12, 2015.